Recombinant Protein Receptor Tyrosine Kinases ROR1 and ROR2

The ROR family of proteins includes ROR1 and ROR2 – receptor tyrosine kinases. ROR1 is especially interesting to pharmacologists as it has only been observed in cancerous and embryonic cells, and never in healthy adult tissue. This makes it a strong therapeutic target for the treatment of several types of cancer.

Many different therapies are under development that target ROR1, including Oncternal’s Cirmtuzumab.

Recombinant Protein Receptor Tyrosine Kinases ROR1 and ROR2

Domains of the ROR1 Receptor Tyrosine Kinase

ROR1’s extracellular domain has three well-defined domains. These are a frizzled domain, a kringle domain and an immunoglobin-like (Ig) domain (Borcherding et al., 2014). It has been found that the use of antibodies, which target the different domains of ROR1, for the treatment of leukemia cell lines results in a significantly different efficacy (Daneshmanesh et al., 2013).

ACROBiosystems can supply researchers with a full range of human model ROR1 proteins. These include products for the complete ECD of all of ROR1 domains, and also for its individual domains.

Molecule Domain Cat. No. Structure
ROR1 Ig-like RO1-H5221 RO1-H5221
ROR1 Frizzled RO1-H5222 RO1-H5222
ROR1 Kringle RO1-H5223 RO1-H5223
ROR1 Full ECD RO1-H522y RO1-H522Y

As well as the domain proteins, ACROBiosystems also provide two pre-biotinylated forms of ROR1 (ECD) that have been produced using avitag technology.

This method involves the conjugation of biotin onto an Avitag that is located at the protein’s C-terminus. This location-specific labeling technique provides several benefits when compared to conventional NHS-labeling – the native structure of the protein is retained and the labeling bioactivity and efficiency is completely uniform.

Pre-Biotinylated ROR1 Proteins from ACROBiosystems

ACROBiosystems pre-biotinylated ROR1 proteins have been used to screen for anti-ROR1 mAbs.  In addition, these proteins are also available for animal research using rat and mouse models.

Molecule Cat. No. Species Structure
ROR1(Biotion-Labeled) RO1-H82F4 RO1-H82F4-STC1
ROR1(Biotion-Labeled) RO1-H821y RO1-H821y-STC1
ROR1 RO1-H5250 RO1-M5250-STC1
ROR1 RO1-M5221 RO1-M5221-STC1
ROR1 RO1-M5250 RO1-M5250-STC1
ROR1 RO1-R5221 RO1-R5221-STC1

ROR1 shares 58% of its homology with ROR2, meaning cross-reactivity with ROR2 can be a problem when using an anti-ROR1 reagent. Comparative analysis must often be employed to rule out this problem. To help solve this problem, ACROBiosystems supplies the following ROR2 proteins for use in human and murine models.  

Molecule Cat. No. Species Structure
ROR2 RO2-H52E5 RO2-H52E5-STC1
ROR2 RO2-H5251 RO2-H5251-STC1
ROR2 RO2-M5253 RO2-M5253-STC1
ROR2 RO2-H82E3 RO2-H82E3-STC1

About ACROBiosystems

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Their mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. They supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, ACROBiosystems delivers solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. ACROBiosystems empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.

Sponsored Content Policy: publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jan 27, 2024 at 3:45 AM


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2024, January 27). Recombinant Protein Receptor Tyrosine Kinases ROR1 and ROR2. News-Medical. Retrieved on May 20, 2024 from

  • MLA

    ACROBiosystems. "Recombinant Protein Receptor Tyrosine Kinases ROR1 and ROR2". News-Medical. 20 May 2024. <>.

  • Chicago

    ACROBiosystems. "Recombinant Protein Receptor Tyrosine Kinases ROR1 and ROR2". News-Medical. (accessed May 20, 2024).

  • Harvard

    ACROBiosystems. 2024. Recombinant Protein Receptor Tyrosine Kinases ROR1 and ROR2. News-Medical, viewed 20 May 2024,

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.